Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity
Authors' conclusion
In this economic evaluation of weight loss drugs for adolescents with severe obesity, we found phentermine-topiramate to be a cost-effective treatment at a willingness-to-pay threshold of $100 000 to $150 000/QALY. Further research is needed to determine long-term drug efficacy and how long adolescents continue treatment.
Study context
- Population
- Simulated cohort of adolescents aged 12 to 17 years (mode, 15 years) with severe obesity (62% female)simulated cohort
- Participants
- 10,000 participants
- Comparison
- Antiobesity drugs vs no treatment
- Outcome
- Incremental cost-effectiveness ratio
- Follow-up
- 10-year horizon
Methodological detailsMarkov microsimulation model, third-party payer perspective, 2023 US dollars, 10-year horizon, data from published literature
- Markov microsimulation model
- Third-party payer perspective
- 2023 US dollars
- 10-year horizon
- Data from published literature
Main finding
As reported in the abstract
Incremental cost-effectiveness ratio vs no treatment
Phentermine-topiramate
$93 620 per QALY
Semaglutide
$1 079 480/QALY
Further findings
- Sleeve gastrectomy and gastric bypass were more effective but more costly, not cost-effective vs phentermine-topiramate at $100 000 to $150 000/QALY
- Sensitivity analysis
Original publication
Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity. JAMA Netw Open. Published 2 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →